Progression of non-small cell lung cancer: Diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A

Kanoh,Yuhsaku; Abe,Tadashi; Masuda,Noriyuki; Akahoshi,Tohru

doi:10.3892/or.2012.2123

Progression of non-small cell lung cancer: Diagnostic and prognostic utility of matrix metalloproteinase-2, C-reactive protein and serum amyloid A

Authors:
- Yuhsaku Kanoh
- Tadashi Abe
- Noriyuki Masuda
- Tohru Akahoshi
View Affiliations

Affiliations: Department of Laboratory Medicine, School of Medicine, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan, Department of Respiratory Medicine, School of Medicine, Tokai University, Isehara, Kanagawa 259-1193, Japan, Department of Respiratory, School of Medicine, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan, Department of General Medicine, School of Medicine, Kitasato University, Sagamihara, Kanagawa 252-0374, Japan
Published online on: November 5, 2012 https://doi.org/10.3892/or.2012.2123
Pages: 469-473

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinase-2 (MMP-2) is known to degrade type IV collagen, which is a major component of the cellular basement membrane, and to be involved in the invasion and metastasis of cancer cells. On the other hand, C-reactive protein (CRP) and serum amyloid A (SAA) are acute inflammatory biomarkers that increase in various conditions including infection, inflammation, malignancy and tissue disturbance. In the present study, we examined the serum levels of MMP-2, CRP and SAA in patients with localized and metastatic non-small cell lung cancer (NSCLC) to establish the clinical significance and changes in these biomarkers during NSCLC progression. In this study, 24 NSCLC patients were diagnosed at the Kitasato University Hospital and compared with 13 healthy controls. Measurement of MMP-2 levels in serum was determined by measuring pro-MMP-2 using a one-step sandwich enzyme immunoassay. CRP and SAA levels in the serum were measured by latex nephelometry. The serum levels of MMP-2, CRP and SAA in metastatic NSCLC patients were significantly higher than in localized NSCLC patients (p<0.01). There was a significant positive correlation between serum MMP-2 and CRP levels as well as SAA levels in metastatic NSCLC patients (p<0.01). Therefore, quantitation of MMP-2, CRP and SAA in NSCLC patients may be an auxiliary indicator to monitor tumor progression and poor prognosis of NSCLC disease.

View Figures

View References

1	Baramova EN, Bajou K, Remacie A, L’Hoir C, Krell HW, Weidle UH and Foidart JM: Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett. 405:157–162. 1997. View Article : Google Scholar : PubMed/NCBI
2	Monea S, Lehit K, Keski-Oja and Mignatii P: Plasmin activates pro-matrix metalloproteinases-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol. 192:160–170. 2002. View Article : Google Scholar : PubMed/NCBI
3	Arbeláez LF, Bergmann U, Tuuttila A, Shanbhag VP and Stigbrand T: Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and α2-macroglobulin. Arch Biochem Biophys. 347:62–68. 1997.PubMed/NCBI
4	Beekman B, Drijfhout JW, Ronday HK and Tekoppele JM: Fluorogenic MMP activity assay for plasma including MMPs complexed to α2-macroglobulin. Ann NY Acad Sci. 878:150–156. 1999.PubMed/NCBI
5	Chen WT and Wang JY: Specialized surface protrusions of invasive cells, invadopodia and lamellipodia, have differential MT1-MMP, MMP-2 and TIMP-2 localization. Ann NY Acad Sci. 878:361–370. 1999. View Article : Google Scholar : PubMed/NCBI
6	Ding S, Zhang M, Zhao Y, Chen W, Yao G, Zhang C, Zhang P and Zhang Y: The role of carotid plaque vulnerability and inflammation in the pathogenesis of acute ischemic stroke. Am J Med Sci. 336:27–31. 2008. View Article : Google Scholar : PubMed/NCBI
7	Alvarez B, Ruiz C, Chacon P, Alvarez-Sabin J and Matas M: Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg. 40:469–475. 2004.PubMed/NCBI
8	Kanoh Y, Akahoshi T, Ohara T, Ohtani N, Mashiko T, Ohtani S, Egawa S and Baba S: Expression of matrix metalloproteinase-2 and prostate-specific antigen in localized and metastatic prostate cancer. Anticancer Res. 22:1813–1818. 2002.PubMed/NCBI
9	Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Changes of proteases and proteinase inhibitors in androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency. Clin Lab. 58:217–225. 2012.PubMed/NCBI
10	Kanoh Y and Ohtani H: Levels of interleukin-6, CRP and α2-macrogloburin in cerebrospinal fluid (CSF) and serum as indicator of blood-CSF barrier damage. Biochem Mol Biol Int. 43:269–278. 1997.
11	dos Anjos BL and Grotto HZ: Evaluation of C-reactive protein and serum amyloid A in the detection of inflammatory and infectious disease in children. Clin Chem Lab Med. 48:493–499. 2010.PubMed/NCBI
12	Fujiwara H, Suchi K, Okamura H, Umehara S, Toda M, Shiozaki A, Kubota T, Ichikawa D, Okamoto K, Ochiai T, Kokuba Y, Sonoyama T and Otsuji E: Elevated serum CRP levels after induction chemoradiotherapy reflect poor treatment response in association with IL-6 in serum and local tumor site in patients with advanced esophageal cancer. J Surg Oncol. 103:62–68. 2011. View Article : Google Scholar
13	Imazio M, Brucato A, Maestroni S, Cumetti D, Dominelli A, Natale G and Trinchero R: Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implication for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 213:1092–1097. 2011. View Article : Google Scholar : PubMed/NCBI
14	Kablak-Ziembicka A, Przewlocki T, Sokolowski A, Tracz W and Podolec P: Carotid intima-media thickness, hs-CRP and TNF-α are independently associated with cardiovascular event risk in patients with atherosclerotic occlusive disease. Atherosclerosis. 214:185–190. 2011.
15	Kanoh Y, Ohara T and Akahoshi T: Acute inflammatory biomarkers in cerebrospinal fluid as indicators of blood cerebrospinal fluid barrier damage in Japanese subjects with infectious meningitis. Clin Lab. 57:37–46. 2011.
16	Smith JW, Colombo JL and McDonald TL: Comparison of serum amyloid A and C-reactive protein as indicators of lung inflammation in corticosteroid treated and non-corticosteroid cystic fibrosis patients. J Clin Lab Anal. 6:219–224. 1992. View Article : Google Scholar : PubMed/NCBI
17	Yap SH, Moshage HJ, Hazenberg BP, Roelofs MH, Bijizet J, Limburg PC, Aarden LA and van Rijiswijk MH: Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta. 1091:405–408. 1991. View Article : Google Scholar
18	Smith JW and McDonald TL: Production of serum amyloid A and C-reactive protein by HepG2 cells stimulated with combinations of cytokines or monocyte conditioned media: the effects of prednisolone. Clin Exp Immunol. 90:293–299. 1992. View Article : Google Scholar
19	Matsuda T, Hirano T, Nagasawa S and Kishimoto T: Identification of α2 macroglobulin as a carrier protein for IL-6. J Immunol. 142:148–152. 1989.
20	Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Levels of acute inflammatory biomarkers in advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol. 39:1553–1558. 2011.
21	Kanoh Y, Ohtani H, Egawa S, Baba S and Akahoshi T: Clinicopathological characteristic of androgen-dependent advanced prostate cancer patients with α2-macroglobulin deficiency. Int J Oncol. 41:39–45. 2012.PubMed/NCBI
22	Mountain C: A new international staging system for lung cancer. Chest. 89:S225–S233. 1986. View Article : Google Scholar : PubMed/NCBI
23	Fujimoto N, Mouri N, Iwata K, Ohuchi E, Okada Y and Hayakawa T: A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies. Clin Chim Acta. 221:91–103. 1993. View Article : Google Scholar
24	Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC and Rha SY: MMP-2 as a putative biomarker for carcinomatosis in gastric cancer. Hepatogastroenterology. 58:2015–2019. 2011.PubMed/NCBI
25	Noh S, Jung JJ, Jung M, Kim TS, Park CH, Lim SJ, Jeung HC, Cheol H, Chung HC and Rha SY: Body fluid MMP-2 as a putative biomarker in metastatic breast cancer. Oncol Lett. 3:699–703. 2012.PubMed/NCBI
26	Safranek J, Pesta M, Holubec L, Kulda V, Dreslerova J, Vrzalova J, Topolcan O, Pesek M, Finek J and Treska V: Expression of MMP-7, MMP-9 TIMP-1 and TIMP-2 mRNA in lung tissue of patients with non-small cell lung cancer (NSCLC) and benign pulmonary disease. Anticancer Res. 29:2513–2517. 2009.PubMed/NCBI
27	Peng WJ, Zhang JQ, Wang BX, Pan HE, Lu MM and Wang J: Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clin Chim Acta. 413:1121–1126. 2012. View Article : Google Scholar : PubMed/NCBI
28	Bataille R, Boccadoro M, Klein B, Durie and Pileri A: C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging system. Blood. 80:733–737. 1992.PubMed/NCBI
29	Firooz N, Albert D, Wallace D, Ishimori M, Berel D and Weisman M: High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 20:588–597. 2011. View Article : Google Scholar : PubMed/NCBI
30	Chua TC, Chong CH, Liauw W, Zhao J and Morris DL: Inflammation markers in blood and serum tumor markers predict survival in patients with epithelial appendiceal neoplasms undergoing surgical cytoreduction and intraperitoneal chemotherapy. Ann Surg. 256:342–349. 2012. View Article : Google Scholar
31	O’Dowd C, McRae LA, McMillian DC, Kirk A and Milroy R: Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol. 5:988–992. 2010.PubMed/NCBI
32	Chan DC, Chen CJ, Chu HC, Chang WK, Yu JC, Chen YJ, Wen LL, Huang SC, Ku CH, Liu YC and Chen JH: Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 14:84–93. 2007. View Article : Google Scholar : PubMed/NCBI
33	Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratanr E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S and Santin AD: Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br J Cancer. 101:335–341. 2009. View Article : Google Scholar : PubMed/NCBI
34	Liu C, Pan C, Shen J, Wang H and Yong L: Identification of serum amyloid A in the serum of gastric cancer patients by protein expression profiling. Oncol Lett. 3:1259–1262. 2012.PubMed/NCBI